No Data
No Data
Erasca To Present Preliminary SEACRAFT-1 Phase 1 Data For Naporafenib Plus Trametinib In RAS Q61X Mutant Solid Tumors As Oral Presentation At 36th EORTC-NCI-AACR Symposium
Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium
Bullish Erasca Insiders Loaded Up On US$3.97m Of Stock
Erasca, Inc. (NASDAQ:ERAS) Is Favoured by Institutional Owners Who Hold 61% of the Company
Erasca to Present at Upcoming Investor Conferences in September
Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation
I Am 102927471 :